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Precursor T-cell acute lymphoblastic leukemia (T-ALL) remains
an important challenge in pediatric oncology. Because of the
particularly poor prognosis of relapses, it is vital to identify
molecular risk factors allowing early and effective treatment
stratiﬁcation. Activating NOTCH1 mutations signify a favorable
prognosis in patients treated on ALL–BFM protocols. We have
now tested if NOTCH pathway activation at different steps has
similar clinical effects and if multiple mutations in this pathway
function synergistically. Analysis of a validation set of 151
T-ALL patients and of the total cohort of 301 patients conﬁrms
the low relapse rate generally and the overall favorable effect of
activating NOTCH1 mutations. Subgroup analysis shows that
the NOTCH1 effect in ALL–BFM is restricted to patients with
rapid early treatment response. Inactivation of the ubiquitin
ligase FBXW7 is associated with rapid early treatment response
and synergizes with NOTCH1 receptor activation. However,
the effect of FBXW7 inactivation is separable from NOTCH1
activation by not synergizing with NOTCH1 mutations in
predicting favorable long-term outcome, which can probably
be explained by the interaction of FBXW7 with other clients.
Finally, the comparison with other European protocols sug-
gests that the NOTCH effect is treatment dependent generally
and may depend on the intensity of central nervous system-
directed therapy speciﬁcally.
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Introduction
Acute lymphoblastic leukemia (ALL) represents the most
common malignant disease in children. Precursor T-cell ALL
(T-ALL) accounts for B10–15% of pediatric leukemias.
1
Although the prognosis of ALL in children, in general and of
T-ALL in particular, has dramatically improved in recent years,
the prognosis of relapsed T-ALL remains dismally poor.
2
Therefore, it is important to distinguish patients with a high risk
(HR) of relapse and who likely beneﬁt from more intensive
treatment from those patients with a favorable risk proﬁle
in whom treatment intensity may potentially be reduced.
1
In the ALL–Berlin–Frankfurt–Mu ¨nster (BFM) 2000 protocol, the
response to early induction therapy is assessed by measuring
the prednisone response after the ﬁrst week of treatment.
3 In
patients with a poor prednisone response treatment is intensi-
ﬁed, which has markedly improved treatment outcome in
pediatric ALL. In this ALL–BFM protocol response assessment
to induction treatment is reﬁned by measuring the minimal
residual disease (MRD) kinetics.
4,5 Nevertheless, conceptually,
it would be preferable to identify high-risk patients already at
diagnosis, which would enable early stratiﬁcation and intensi-
ﬁcation of induction therapy. At the same time, it may be
possible to identify those patients, who can be cured with less
intensive treatment. In T-ALL, genetic risk factors that are
common enough to stratify patients have only recently been
identiﬁed. Activating mutations of the transmembrane receptor
NOTCH1 occur in 450% of all childhood T-ALL patients
6 and
have previously been shown to signify a favorable prognosis in
the context of the ALL-BFM protocol-based treatment
7 and
subsequently also in other similar protocols,
8–10 although not in
others.
11–17 Under physiological conditions, NOTCH1 is
activated by ligand binding, followed by proteolytic cleavages
that liberate the intracellular part of NOTCH1 (ICN1) in the
cytoplasm. ICN1 is then translocated to the nucleus and, in
concert with other transcriptional activators, induces the
expression of target genes that include important oncogenic
pathways, such as c-MYC.
18 The effect of ICN1 is limited by
ubiquitination and degradation. This process is regulated by the
E3 ubiquitin ligase, FBXW7, that binds to the C-terminal PEST
domain of ICN1.
19,20 Interestingly, inactivating mutations of
FBXW7 have recently been found to be common
in T-ALL.
21–23 These mutations are expected to increase the
activity of the NOTCH1 pathway in a similar manner as the
NOTCH1-PEST mutations do.
21,23
In this study, we show in a large group of 301 children with
T-ALL, who were treated on the ALL–BFM 2000 protocol that
(1) the overall favorable effect of NOTCH1 receptor activation
on long-term outcome can be conﬁrmed in a larger data set,
(2) this effect is restricted to those patients with a rapid early
treatment response, (3) inactivating FBXW7 mutations occur in
14% of all T-ALL and are associated with a remarkably favorable
prednisone response, but (4) that these FBXW7 mutations do not
have a signiﬁcant effect on long-term outcome by themselves
and (5) do not detectably synergize with NOTCH1 receptor
mutations to specify a group of patients with a particularly
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www.nature.com/leufavorable long-term outcome. Finally, a systematic comparison
of different European treatment protocols suggests that the
variable effects of NOTCH mutations on prognosis likely
depends on differences in treatment generally and on the type
and intensity of central nervous system (CNS)-directed therapy
speciﬁcally.
Materials and methods
Patients and samples
From August 1999 through February 2008, a total of 545
patients with T-ALL were eligible for treatment in the multi-
center ALL–BFM 2000 trial (no non-Hodgkin’s lymphoma
patients included). This study was approved by the institutional
review board of the Hannover Medical School and other
participating institutions. Informed consent was obtained in
accordance with the Declaration of Helsinki. This trial enrolled
pediatric patients up to 18 years of age from 70 different
treatment centers in Germany, Austria and Switzerland. This
study includes a subgroup of 301 patients from Germany and
Switzerland. The subjects were selected on the basis of
availability of sufﬁcient amounts of DNA for molecular analysis.
The group includes 150 of the 157 patients whose NOTCH1
receptor mutation status has been reported previously.
7 In all,
7 of these 157 patients were excluded from the analysis
presented in this study, because of either lack of available
DNA (2), protocol violations (3) or age 418 years (2). In all, 151
patients have not been reported previously regarding NOTCH1
status. The clinical parameters (age, gender, white blood cell
count at diagnosis, prednisone response, MRD at day 78) of this
subgroup of patients did not differ signiﬁcantly from the entire
ALL–BFM 2000 cohort.
Mononuclear cells were isolated from bone marrow samples
and stored in liquid nitrogen or at  801C until DNA extraction.
All bone marrow samples contained a blast percentage of 80%
or more. Immunophenotyping was carried out as previously
described,
24 and the subclassiﬁcation of T-ALL was performed
according to the guidelines of the European Group for
Immunological Characterization of Leukemias.
25 The presence
of TEL/AML1, BCR/ABL and MLL/AF4 fusion transcripts was
analyzed as described previously.
26,27
Early in vivo response to prednisone, deﬁned as the cytoreduc-
tion (number of peripheral blood blasts per microliter on day 8) to
a 7-day prednisone treatment prophase and a single dose of
intrathecal methotrexate on day 1 served to assess the effect of
early treatment.
3 According to prednisone response, patients were
classiﬁed into good responders (o1000 blasts/ml at day 8) or poor
responders (X1000 blasts/mla td a y8 ) .T r e a t m e n tr e s p o n s ew a s
further deﬁned by determination of MRD kinetics that were
assessed at two different time points (TPs), at days 33 (TP1) and 78
(TP2) of treatment, respectively.
5,28–30 As previously described,
allele-speciﬁc oligonucleotide–PCR protocols were used for
quantitative detection of leukemic clone-speciﬁc immunoglobulin
and T-cell-receptor gene rearrangements on a LightCycler
instrument (Roche Diagnostics, Mannheim, Germany).
31 At both
TPs, an unfavorable MRD status (X10
 4) was deﬁned by the
presence of at least one leukemic cell in 10
4 cells, whereas a
favorable MRD status (o10
 4) was deﬁned as the absence of
detectable leukemic cells in 10
4 cells.
7 Complete remission was
deﬁned as o5% blasts in the regenerating bone marrow, the
absence of leukemic blasts in the peripheral blood and
cerebrospinal ﬂuid, and no evidence of localized disease. Relapse
was deﬁned as recurrence of lymphoblasts or localized leukemic
inﬁltrates at any site.
Mutational analysis of NOTCH1 and FBXW7
Sequencing of NOTCH1 has been performed as described
previously.
7 Sequencing of FBXW7 was carried out following
PCR ampliﬁcation of exons 9 and 10 that have previously been
reported to be the most frequently mutated regions. Primer
sequences for exon 9 are: forward 50-ccaggccagagctatcataac-30;
reverse 50-agacaaaacgctatggctttcc-30; and for exon10 are:
forward 50-aaccttgactaaatctaccatgtt-30; reverse 50-ctggatcag
caatttgacagtg-30. PCR-ampliﬁed fragments were sequenced
by GATC biotech (Konstanz, Germany).
Statistical analyses
Event-free survival (EFS) was deﬁned as the time from diagnosis
to the date of last follow-up in complete remission or ﬁrst event.
Events were resistance to therapy (non-response), relapse,
secondary neoplasm or death from any cause. Failure to achieve
remission because of the early death or non-response was
considered as events at time zero. Survival was deﬁned as
the time of diagnosis to death from any cause or last follow-up.
The Kaplan–Meier method was used to estimate survival rates,
differences were compared with the two-sided log-rank test.
The Cox proportional hazards model was used for uni- and
multivariate analyses. Cumulative incidence (CI) functions
for competing events were constructed by the method of
Kalbﬂeisch and Prentice, and were compared with the Gray’s
test. Results are presented as estimated probability of 5-years EFS
(pEFS) and estimated CI of relapse (pCIR) with ± s.e. Differences
in the distribution of individual parameters among patient
subsets were analyzed using the Fisher’s exact test for
categorized variables and the Mann–Whitney U-test for
continuous variables. Logistic regression was used to analyze
the effect of mutations on response variables (prednisone
response, MRD). All statistical analyses were conducted using
the SAS program (SAS-PC, Version 9.1, SAS Institute Inc, Cary,
NC, USA).
Results
The analysis of an extended group of BFM patients
with T-ALL conﬁrms the favorable effect of NOTCH1
receptor mutations on early treatment response and
long-term outcome
Previously, we reported the analysis of 157 T-ALL patients, who
were enrolled in the ALL–BFM study and demonstrated that
NOTCH1 mutations represent an independent molecular
marker that speciﬁes a large group of patients with a favorable
early treatment response and excellent long-term outcome.
7 We
have now extended this analysis to study a large group of 301
patients enrolled in the ALL–BFM 2000 study. The group
includes 150 of the 157 patients from our previous report and
a validation set of 151 patients who have not been included in
our previous analysis. As reported previously, the NOTCH1
mutational status correlates with the common cortical immuno-
phenotype; these factors remain independent in a multivariate
analysis. We identiﬁed 150 (50%) T-ALLs with heterozygous
somatic NOTCH1 mutations, 94 (31.2%) in the heterodimeriza-
tion domain, 29 (9.6%) in the transactivation domain-PEST
domain and 27 (9%) in both. The distribution of mutations was
similar in both sets (data not shown).
Prednisone response was available for 149/150 patients with
NOTCH1 mutations, and for 145/151 patients without
NOTCH1 mutations (Table 1). It was observed that patients
with NOTCH1 mutations show a better prednisone response
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Table 1).
The induction phase of the ALL–BFM 2000 protocol clears
MRD more effectively in NOTCH1-mutated patients than in
patients without a NOTCH1 mutation.
7 MRD data on day 33
were available in 267 patients (138 NOTCH1 mutated,
129 NOTCH1 non-mutated) and in 274 patients on day 78
(140 NOTCH1 mutated and 134 NOTCH1 non-mutated). On
both days of MRD measurements, NOTCH1-mutated patients
showed a more favorable response (P¼0.003, respectively,
Po0.0001; Table 1).
As reported previously, long-term outcome of the NOTCH1-
mutated group was signiﬁcantly better (pEFS 87%) than in the
non-mutated group (pEFS 74%; P¼0.005; Figure 1a). The two
very late events in the NOTCH1-mutated group are second
malignancies. Furthermore, the likelihood for developing a
relapse was only 7% in the mutated group but 17% in the non-
mutated group (P¼0.007; Figure 1b). A separate analysis of the
second group of patients who had not been reported previously
conﬁrms the signiﬁcant difference in pCIR and the trend toward
better EFS
7 (Figures 1c and d). Overall, the results obtained by
the analysis of a large group of patients conﬁrm that activating
NOTCH1 mutations are strongly associated with favorable early
treatment response and also with excellent long-term outcome.
Clinical data on the presence of initial CNS involvement were
available in 254 patients (no information about CNS involve-
ment for the other 47 patients). The incidence of CNS
involvement was similar in NOTCH1-mutated and NOTCH1-
non-mutated patients (12/127 (9%) versus 18/127 (12%)).
Furthermore, the incidence of relapses with CNS involvement
was low and similar in NOTCH1-mutated and -non-mutated
patients both, in the entire group (pCIR 2±1% versus 4±2%),
and also in the high-risk subgroup of patients (pCIR 3±3%
versus 5±3%).
The favorable effect of NOTCH1 receptor activation is
higher in the standard and intermediate risk groups
The large cohort of patients now enabled us to perform
subgroup analysis and we thus assessed whether the effect of
NOTCH1 mutations differs in the conventionally deﬁned risk
groups that are stratiﬁed according to in vivo treatment
response. The standard risk group (SR) of the ALL–BFM 2000
protocol is deﬁned by a prednisone good response and a
negative MRD result on days 33 and 78, whereas HR patients
either show a PPR, an MRD response of X10
 3 on day 78 or
both. The intermediate risk group (MR) regroups all remaining
patients.
32,33 In addition, patients who are BCR/ABL or MLL/AF4
positive are classiﬁed as HR. In our cohort of 301 T-ALL
patients, 168 patients were thus stratiﬁed to the SR or MR
groups, whereas 133 patients were stratiﬁed to the HR group.
When comparing patients with or without NOTCH1 muta-
tions in the SR/MR group, the NOTCH1-mutated group had an
excellent pEFS of 95%, which compared with 83% in the non-
mutated group (P¼0.02; Figure 2a). There is also a trend in the
relapse rate, although the number of relapses is low. Speciﬁ-
cally, the pCIR was only 4% (4/99) in the NOTCH1-mutated but
11% (7/69) in the NOTCH1-non-mutated group (Figure 2b;
P¼0.11). By contrast, in the HR group no difference in
pEFS was observed between NOTCH1-mutated (72%) and
-non-mutated patients (66%; Figure 2c), although there was a
non-signiﬁcant trend toward a lower rate of relapse in the
NOTCH1-mutated compared with the NOTCH1-non-mutated
group (P¼0.13; Figure 2d). In a Cox regression analysis of EFS,
including the variables risk group SR/MR versus HR, NOTCH1
mutation or an interaction term (NOTCH1 mutations in SR/MR
versus other) and stem cell transplantation as time dependent
variable, the interaction was signiﬁcant (relative risk¼0.32,
95% conﬁdence interval 0.12–0.86, P¼0.024). This was not the
case for relapse risk, but the simple effect of NOTCH1
was signiﬁcant (relative risk 0.43, 95% conﬁdence interval
0.20–0.92). Therefore, the favorable effect of NOTCH1 muta-
tions seems to be restricted to those leukemias with a genetic
proﬁle that already speciﬁes a good response to the ALL–BFM
treatment strategy. By contrast, NOTCH1 activation does not
seem to override the genetic proﬁle that speciﬁes the empirically
deﬁned HR group.
FBXW7 mutations predict good prednisone and early
MRD response but do not signify favorable late MRD
response or long-term outcome
Inactivating FBXW7 mutations have previously been reported to
be common in T-ALL
21–23 and are expected to activate the
NOTCH pathway. We hypothesized that FBXW7 mutations may
have a similar clinical effect as activating NOTCH1 mutations
Table 1 Activating NOTCH1 mutations signify favorable early treatment response in children with T-ALL
PPR (%) PGR (%) Data not available P
z
Prednisone response (day 8)
a
NOTCH1 mutated 47 (32) 102 (68) 1 P¼0.002
NOTCH1 non-mutated 72 (50) 73 (50) 6
Unfavorable (%) Favorable (%) Data not available P
z
MRD (day 33)
b
NOTCH1 mutated 91 (66) 47 (34) 12 P¼0.003
NOTCH1 non-mutated 106 (82) 23 (18) 22
MRD (day 78)
b
NOTCH1 mutated 37 (26) 103 (74) 10 Po0.0001
NOTCH1 non-mutated 76 (57) 58 (43) 17
Abbreviations: MRD, minimal residual disease; PGR, prednisone good response; PPR, prednisone poor response; T-ALL, T-cell acute
lymphoblastic leukemia.
zP-value; Fisher’s test.
aPPR: X1000 leukemic blood blasts/ml on treatment day 8; PGR: o1000/ml.
bUnfavorable MRD: X10
 4; favorable MRD: o10
 4.
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Leukemiaand that these two types of mutations may synergize to sensitize
leukemia cells for treatment. We have thus determined the
FBXW7 mutation status and analyzed its effect on treatment
efﬁcacy. We identiﬁed heterozygous FBXW7 mutations in
42 (14%) of 301 T-ALL samples (Table 2). All of these mutations
are located in exons 9 and 10 of the gene, which encode the
C-terminal-binding site between the ligase and the substrate.
These mutations are predicted to disrupt the binding between
FBXW7 and ICN1. In the N-terminal part of the protein, FBXW7
contains a homodimerization domain that is still functional in
the mutated form of the ubiquitin ligase. Therefore, the mutated
monomer sequesters the product of the normal allele in a non-
functional dimer and is thus thought to function in a dominant-
negative manner.
21,34
We grouped the patients according to their FBXW7 muta-
tional status and compared their early treatment response
(assessed by prednisone response and MRD kinetics). Most
patients with FBXW7 mutations responded well to prednisone
(88%), but only 55% in the FBXW7-non-mutated group
(P¼0.00003; Table 2). The MRD kinetics at both TPs
were available in 39/42 patients with FBXW7 mutations. In this
group, a favorable MRD response on days 33 and 78 was
observed in 16/39 and in 28/39 patients. On day 33, the
difference between the FBXW7-mutated and FBXW7-non-
mutated groups was signiﬁcant (P¼0.03), whereas FBXW7
mutations lost their signiﬁcant predictive value on day 78,
although there was still a trend (P¼0.08). Figure 3a shows that
patients with or without FBXW7 mutations have a similar pEFS
(76% compared with 81%, P¼0.48) and a similar pCIR (10%
compared with 13%, P¼0.6, Figure 3b).
These data indicate that FBXW7 mutations confer a high
sensitivity of T-ALL blasts to glucocorticoids and possibly
intrathecal methotrexate, but also that the difference
in treatment response between mutated and non-mutated cells
is leveled by the drugs that are used later during induction,
intensiﬁcation and re-induction.
NOTCH1 and FBXW7 mutations function together to
result in excellent early treatment response but not
to generate a more favorable long-term outcome
Because activating mutations of the NOTCH1 receptor and
inactivating mutations of the E3 ligase that targets the active
ICN1 for degradation by the proteasome are expected to
function in a similar manner on the NOTCH pathway, we
hypothesized that these two types of mutations may synergize
clinically. Furthermore, it has been reported previously that
T-ALL mutations in the NOTCH1-PEST domain and of FBXW7
are mutually exclusive.
21,22 We also observed this relationship
in the cohort of patients analyzed here, although there was one
exception of a patient with a NOTCH1-PEST and a FBXW7
mutation. In all the other 29 patients with a mutation in both
genes, the NOTCH1-heterodimerization domain was mutated.
This almost complete mutual exclusiveness of FBXW7 and
Figure 1 Activating NOTCH1 mutations predict an excellent long-
term outcome in T-ALL. (a) Kaplan–Meier estimate of the pEFS in
NOTCH1-mutated and NOTCH1-non-mutated patients from the total
cohort (n¼301). (b) pCIR in NOTCH1-mutated and NOTCH1-non-
mutated patients from the total cohort (n¼301). (c) Kaplan–Meier
estimate of the pEFS in NOTCH1-mutated and NOTCH1-non-mutated
patients from the validation set (n¼151). (d) pCIR in NOTCH1-
mutated and NOTCH1-non-mutated patients from the validation set
(n¼151). The 18 events in the NOTCH1-non-mutated group were 14
relapses, 3 deaths in continuous complete remission and 1 death
before complete remission. The 10 events in the NOTCH1-mutated
group were 5 relapses, 4 deaths in continuous complete remission and
1 death before complete remission.
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LeukemiaNOTCH1-PEST mutations suggests that no additional selection
advantage is provided by a NOTCH1-PEST and FBXW7 double
mutation and that the biological function in T-ALL of both types
of mutation is similar.
In adults with T-ALL, FBXW7 mutations have previously been
reported to add signiﬁcant prognostic value to the NOTCH1
mutational status.
10 Therefore, we next assessed, if the
combination of both mutations is also beneﬁcial in the context
of the pediatric ALL–BFM study. We compared the outcome in
the 30 (10%) patients with mutations in both, NOTCH1 and
FBXW7 genes, to the 120 (40%) patients with mutations in
NOTCH1 only, to the 12 (4%) patients with FBXW7 mutations
only, and to those 139 (46%) without mutation in either gene.
Prednisone response data were available in 294 patients. In the
group of 30 patients with the combination of NOTCH1 and
FBXW7 mutations, only 2 (7%) showed a PPR, whereas the
group of 119 patients with a NOTCH1 mutation only or the
group of 12 patients with a FBXW7 mutation only showed a PPR
in 45 (38%) and 3 (25%), respectively (Table 3). The 133
patients with neither mutation (for which prednisone response
was available) showed a PPR in 69 (52%). In a logistic
regression analysis both NOTCH1 and FBXW7 mutations had
a signiﬁcant inﬂuence on the prednisone good responder rate
(P¼0.01 and 0.001).
We next analyzed the MRD kinetics after 33 (available in 267
patients) and 78 days (available in 274 patients) of induction
treatment. On day 33, the group with mutations in both genes
showed a signiﬁcantly lower MRD load (16/29; 55% favorable)
when compared with the groups with either a NOTCH1
(31/109; 28% favorable) or a FBXW7 mutation (0/10 favorable),
or with neither mutation (23/119; 19% favorable). On day 78,
the group with the NOTCH1 and FBXW7 mutations showed a
favorable MRD load in 24/30 (80%) patients, which did not
differ signiﬁcantly from the group with either NOTCH1 (79/110;
72%) or FBXW7 mutations alone (4/9; 44%). As expected, the
NOTCH1-mutated and the double-mutated groups showed a
signiﬁcantly more frequent favorable MRD load than the group
with neither mutation (54/125; 43%). In a logistic regression
analysis NOTCH1 but not FBXW7 mutations had signiﬁcant
inﬂuence on the MRD-load at both TPs (P¼0.01 and o0.0001
versus P¼0.09 and 0.43).
Long-term outcome and the rate of relapse of patients with
double mutations are no different to those with NOTCH1
mutations only. Patients with FBXW7 mutations only tend to
show a less favorable outcome with 5/12 patients having had an
event (one relapse, two deaths in continuous complete
remission, one death before complete remission and one patient
with a secondary malignancy). Unfortunately, the patient
number in this group is only 12 and thus far too small for
reaching meaningful conclusions in this subgroup. As expected,
the advantage of the NOTCH1-pathway-mutated groups com-
pared with the patients without a mutation is maintained in this
subgroup analysis (Supplementary Figure 1a and 1b).
We conclude that in the context of the ALL–BFM protocol-
based treatment, NOTCH1 and FBXW7 mutations function
together to result in a favorable early treatment response.
However, this additive effect is not maintained with regard to
long-term outcome of children and adolescents with T-ALL.
Figure 2 The favorable effect of activating NOTCH1 mutations on
long-term outcome is restricted to the SR/MR group. (a) Kaplan–Meier
estimate of the probability of pEFS in NOTCH1-mutated and
NOTCH1-non-mutated SR/MR patients. (b) pCIR in NOTCH1-mutated
and NOTCH1-non-mutated SR/MR patients. (c) Kaplan–Meier esti-
mate of the pEFS in NOTCH1-mutated and NOTCH1-non-mutated HR
patients. (d) pCIR in NOTCH1-mutated and NOTCH1-non-mutated
HR patients.
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T-ALL in childhood and adolescence still represents one of the
important challenges in pediatric oncology. Although the
probability of cure has signiﬁcantly improved with modern
protocols and long-term disease-free survival rates of B80% can
now be obtained, the prognosis of relapses is still dismal.
Therefore, it is critical to identify those patients at HR, who may
beneﬁt from intensiﬁed treatment regimens. At the same time, it
is important to identify those patients with a favorable risk
proﬁle, who may beneﬁt from a reduction of treatment intensity.
The measurement of the kinetics of leukemia clearance during
early induction has proved to be a successful strategy to stratify
patients and to improve the prognosis of HR patients in pre-B-
ALL and in T-ALL.
32 MRD-based stratiﬁcation at later TPs has
been shown to be even more effective to predict survival.
33
However, the MRD-based late identiﬁcation of HR patients in
the ALL–BFM 2000 study after induction treatment is a potential
disadvantage of this strategy. Conceptually, it is preferable to
develop molecular prognostic markers that can be studied at the
time of diagnosis thus enabling a stratiﬁcation of treatment from
its beginning. In contrast to preB-ALL, valid and clinically useful
prognostic markers in T-ALL are only beginning to emerge. The
analysis of gene expression proﬁles in a limited number of
patients suggested that the expression of homeotic genes
(HOX11, HOX11L2) and transcripts that relate to the stage of
maturation of the T-ALL clone (TAL1, LMO1/2, LYL) may be of
prognostic value.
35 However, the value of these markers has
been controversial
12,36 and, more generally, the usefulness
of mRNA-based markers is probably limited in the context of
multicenter protocols, because of the inﬂuence of pre-analytical
handling.
37
A number of mutations have previously been identiﬁed in
several genes whose products are involved in oncogenic
pathways, such as phosphoinositide 3-kinases–AKT and trans-
forming growth factor-b.
38,39 Most of these oncogenic mutations
are present in only a small subset of patients, and most of them
failed to stratify risk in pediatric T-ALL. In contrast, some
mutations, such as deletions of the PTEN or the CASP8AP2
genes, were shown to be of negative prognostic value.
38,39
Other factors might also inﬂuence the outcome of the patients
and would thus be candidates to be included as components of
a multifaceted molecular risk proﬁle of T-ALL. NOTCH1
mutations do not make a difference for the HR patients, but
other mutations might do.
Activating mutations of the NOTCH1 receptor are common in
T-ALL.
6 However the effect of NOTCH1 mutations on the
prognosis of T-ALL has been controversial since our ﬁrst report
in 2006.
7 Although the favorable effect of activating NOTCH1
mutations on treatment outcome was conﬁrmed by study groups
with BFM-type treatment strategies,
8,9 NOTCH1 mutations did
not predict favorable treatment response in the context of other
Table 2 Inactivating FBXW7 mutations specify an excellent prednisone response, but marginal effects on MRD kinetics
PPR (%) PGR (%) Data not available P
z
Prednisone response (day 8)
a
FBXW7 mutated 5 (12) 37 (88) 0 P¼0.00003
FBXW7 non-mutated 114 (45) 138 (55) 7
Unfavorable (%) Favorable (%) Data not available P
z
MRD (day 33)
b
FBXW7 mutated 23 (59) 16 (41) 3 P¼0.03
FBXW7 non-mutated 174 (76) 54 (24) 31
MRD (day 78)
b
FBXW7 mutated 11 (28) 28 (72) 3 P¼0.08
FBXW7 non-mutated 102 (43) 133 (57) 24
Abbreviations: MRD, minimal residual disease; PGR, prednisone good response; PPR, prednisone poor response.
zP-value; Fisher’s test.
aPPR: X1000 leukemic blood blasts/ml on treatment day 8; PGR: o1000/ml.
bUnfavorable MRD: X10
 4; favorable MRD: o10
 4.
Figure 3 Inactivating FBXW7 mutations do not predict better long-
term outcome in T-ALL. (a) Kaplan–Meier estimate of the pEFS in
FBXW7-mutated and FBXW7-non-mutated patients. (b) pCIR in
FBXW7-mutated and FBXW7-non-mutated patients.
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11–17 In the light of this controversy, one of
the important ﬁndings of this study is that the favorable effect of
NOTCH1 mutations is conﬁrmed by this analysis of a large
group of BFM patients. This ﬁnding suggests that the effect of
NOTCH1 mutations depends on the treatment protocol. Indeed,
the long-term outcome of NOTCH1-non-mutated patients is
similar in most modern protocols including BFM,
16,17 whereas
the generally more favorable outcome of T-ALL in BFM-type
treatment strategies is caused by a particularly good outcome in
the NOTCH1-mutated group. This may indicate that NOTCH1-
mutated T-ALLs are particularly sensitive to the BFM strategy.
More speciﬁcally, the favorable effect of NOTCH1 mutations in
BFM protocols is highly signiﬁcant in the standard and
intermediate risk groups, whereas NOTCH1 mutations are
neutral in the high-risk group that consists of patients with poor
early treatment response. The chemotherapy in the European
Organisation for Research and Treatment of Cancer (EORTC)
protocols is in large parts similar to the one in BFM protocols,
but EORTC does not perform cranial irradiation. Interestingly,
the EORTC protocols also show a signiﬁcantly better early
treatment response and a trend towards better pEFS in the
NOTCH1-mutated group with favorable early treatment
response. In striking contrast to the BFM patients, EORTC HR
patients with NOTCH1 mutations have a dismal prognosis.
16
Signiﬁcantly, Clappier et al.
16 report that CNS relapses are more
common in the NOTCH1-mutated high-risk group, whereas
CNS relapses are rare in BFM-treated patients in general but also
in the high-risk group in particular. One could speculate that the
BFM type chemotherapy alone is able to prevent CNS relapses
in the NOTCH1-mutated good responders, but not in the poor
responders. A possible mechanistic link between NOTCH1
activation and T-ALL CNS tropism has recently been suggested
by the ﬁnding that in mice the chemokine receptor CCR7 is
controlled by NOTCH1 and required for targeting leukemic
cells to the CNS.
40 In this context, it is intriguing that one of the
major differences between the BFM and the EORTC or
the Dutch Childhood Oncology Group treatment strategies lies
in the use of cranial radiotherapy in BFM but not in EORTC or
Dutch Childhood Oncology Group.
16,17 This comparison
suggests that NOTCH1-mutated T-ALL with poor early treatment
response tend to cause CNS relapses and that this propensity
may be effectively limited by cranial radiotherapy. Despite the
generally debatable role of prophylactic cranial radiotherapy in
childhood ALL,
41 NOTCH1-mutated patients with T-ALL and
poor early treatment response may thus constitute a subgroup of
children, who may beneﬁt from radiotherapy or other modes of
intensiﬁed CNS-directed therapy.
Inactivation of FBXW7 is expected to activate the NOTCH
pathway. We thus hypothesized that T-ALL with inactivating
FBXW7 mutations would be clinically similar to those with
activating NOTCH1 mutations. Further, we hypothesized that
inactivating FBXW7 mutations and activating NOTCH1 muta-
tions may clinically synergize. In line with these hypotheses, this
study shows that FBXW7 mutations are associated with an
excellent prednisone response and also with rapid clearance
of the leukemia from the bone marrow. Furthermore, T-ALL
patients with NOTCH1/FBXW7 double mutations show more
frequent favorable MRD at day 33 of induction than those with
mutations in either NOTCH1 or FBXW7. Surprisingly, however,
there were no signiﬁcant differences between these groups in
the frequency of favorable MRD at day 78 or in the frequency of
relapse and pEFS. Therefore, the effects of NOTCH pathway
activation by either receptor mutations or inactivation of the E3
ubiquitin ligase are separable. Although these mutations seem to
be similar and to be additive or synergistic early in treatment,
FBXW7 inactivation inﬂuences neither treatment response at the
end of induction nor long-term outcome. The mechanism of the
separable effect of NOTCH1 receptor activation and FBXW7
inactivation must remain an open question at this point.
However, this difference may possibly be explained by the
activation of the receptor being less pleiotropic than the
inactivation of the negative regulator FBXW7, because this E3
ubiquitin ligase does not only interfere with the NOTCH
pathway but also with other important oncogenic pathways
Table 3 Activating NOTCH1 and inactivating FBXW7 mutations function together to specify an excellent prednisone response and early but
not late MRD
PPR (%) PGR (%) Data not available P
z
Prednisone response (day 8)
a
NOTCH1+FBXW7 mutated 2 (7) 28 (93) 0
3
7 5
Po0.00001
NOTCH1 mutated 45 (38) 74 (62) 1
#
P¼0.03
FBXW7 mutated 3 (25) 9 (75) 0
NOTCH1/FBXW7 non-mutated 69 (52) 64 (48) 6
i
P¼0.13
Unfavorable (%) Favorable (%) Data not available P
z
MRD (day 33)
b
NOTCH1+FBXW7 mutated 13 (45) 16 (55) 1
3
7 5
P¼0.0003
NOTCH1 mutated 78 (72) 31 (28) 11
#
P¼0.12
FBXW7 mutated 10 (100) 0 (0) 2
NOTCH1/FBXW7 non-mutated 96 (81) 23 (19) 20
i
P¼0.21
MRD (day 78)
b
NOTCH1+FBXW7 mutated 6 (20) 24 (80) 0
3
7 5
P¼0.0004
NOTCH1 mutated 31 (28) 79 (72) 10
#
P¼0.00001
FBXW7 mutated 5 (56) 4 (44) 3
NOTCH1/FBXW7 non-mutated 71 (57) 54 (43) 14
i
P¼1.00
Abbreviations: MRD, minimal residual disease; PGR, prednisone good response; PPR, prednisone poor response.
zP-value; Fisher’s Test.
aPPR: X1000 leukemic blood blasts/ml on treatment day 8; PGR: o1000/ml.
bUnfavorable MRD: X10
 4; favorable MRD: o10
 4.
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Leukemiaand proteins such as c-MYC, PSEN1, c-JUN, cyclin E1, sterol
regulatory element-binding protein, mammalian target of
rapamycin or Aurora-A.
42–48
In conclusion, in BFM protocols T-ALL patients with FBXW7
mutations show an excellent prednisone and early MRD
response. At this early time, FBXW7 mutations function together
with NOTCH1 mutations. In contrast, this synergy is lost for
long-term outcome. It will now be necessary to validate the
prognostic signiﬁcance of NOTCH1 mutations in a prospective
study possibly with a particular emphasis on its role to predict
the necessity for prophylactic cranial radiotherapy. However,
when interpreting these differences it must be borne in mind that
the BFM and EORTC protocols also differ in other, potentially
important details and that both studies were not designed to be
directly comparable.
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